V3174

antibody from NSJ Bioreagents

Targeting: TYRP1 b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP

Immunocytochemistry (Recommended by provider)

Immunohistochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Antibody Data

Product number

V3174

Provider

NSJ Bioreagents

Product name

TRP1 Antibody

Antibody type

Monoclonal

Antigen

SK-MEL-23 cells were used as the immunogen for this TRP1 antibody.

Description

Protein G purified antibody

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antibody clone number

TA99

Vial size

20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)

Storage

Store the TRP1 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

References

Submitted references

Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.

Braster R, Grewal S, Visser R, Einarsdottir HK, van Egmond M, Vidarsson G, Bögels M
PloS one 2017;12(5):e0177736

---

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.

Vazquez-Lombardi R, Loetsch C, Zinkl D, Jackson J, Schofield P, Deenick EK, King C, Phan TG, Webster KE, Sprent J, Christ D
Nature communications 2017 May 12;8:15373

---

Durable antitumor responses to CD47 blockade require adaptive immune stimulation.

Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC
Proceedings of the National Academy of Sciences of the United States of America 2016 May 10;113(19):E2646-54

---

Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread.

Büll C, Boltje TJ, van Dinther EA, Peters T, de Graaf AM, Leusen JH, Kreutz M, Figdor CG, den Brok MH, Adema GJ
ACS nano 2015 Jan 27;9(1):733-45

---

Key regulatory role of dermal fibroblasts in pigmentation as demonstrated using a reconstructed skin model: impact of photo-aging.

Duval C, Cohen C, Chagnoleau C, Flouret V, Bourreau E, Bernerd F
PloS one 2014;9(12):e114182

---

Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).

Malas S, Harrasser M, Lacy KE, Karagiannis SN
Oncology reports 2014 Sep;32(3):875-86

---

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress.

Mosenson JA, Flood K, Klarquist J, Eby JM, Koshoffer A, Boissy RE, Overbeck A, Tung RC, Le Poole IC
Pigment cell & melanoma research 2014 Mar;27(2):209-20

---

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.

Bonchak JG, Eby JM, Willenborg KA, Chrobak D, Henning SW, Krzywiec A, Johnson SL, Le Poole IC
Archives of biochemistry and biophysics 2014 Dec 1;563:71-8

---

Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.

Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T
Journal of immunology (Baltimore, Md. : 1950) 2013 Jan 1;190(1):489-96

---

Human skin model containing melanocytes: essential role of keratinocyte growth factor for constitutive pigmentation-functional response to α-melanocyte stimulating hormone and forskolin.

Duval C, Chagnoleau C, Pouradier F, Sextius P, Condom E, Bernerd F
Tissue engineering. Part C, Methods 2012 Dec;18(12):947-57

---

New perspectives on the role of vitiligo in immune responses to melanoma.

Byrne KT, Turk MJ
Oncotarget 2011 Sep;2(9):684-94

---

Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo.

Elassiuty YE, Klarquist J, Speiser J, Yousef RM, El Refaee AA, Hunter NS, Shaker OG, Gundeti M, Nieuweboer-Krobotova L, Le Poole IC
Experimental dermatology 2011 Jun;20(6):496-501

---

DNA vaccination: using the patient's immune system to overcome cancer.

Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN
Clinical & developmental immunology 2010;2010:169484

---

Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.

Osen W, Soltek S, Song M, Leuchs B, Steitz J, Tüting T, Eichmüller SB, Nguyen XD, Schadendorf D, Paschen A
PloS one 2010 Nov 30;5(11):e14137

---

Human eyelash characterization.

Thibaut S, De Becker E, Caisey L, Baras D, Karatas S, Jammayrac O, Pisella PJ, Bernard BA
The British journal of dermatology 2010 Feb 1;162(2):304-10

---

Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.

Klarquist J, Barfuss A, Kandala S, Reust MJ, Braun RK, Hu J, Dilling DF, McKee MD, Boissy RE, Love RB, Nishimura MI, Le Poole IC
The American journal of pathology 2009 Dec;175(6):2463-72

---

Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV.

Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M
Journal of immunology (Baltimore, Md. : 1950) 2008 Nov 15;181(10):6829-36

---

Glycolipid-dependent sorting of melanosomal from lysosomal membrane proteins by lumenal determinants.

Groux-Degroote S, van Dijk SM, Wolthoorn J, Neumann S, Theos AC, De Mazière AM, Klumperman J, van Meer G, Sprong H
Traffic (Copenhagen, Denmark) 2008 Jun;9(6):951-63

---

Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand.

Simon AK, Newsom-Davis T, Frayne ME, Ch'en PF, McMichael AJ, Screaton GR
International immunology 2008 Apr;20(4):525-34

---

Uveal melanocytes do not respond to or express receptors for alpha-melanocyte-stimulating hormone.

Li L, Hu DN, Zhao H, McCormick SA, Nordlund JJ, Boissy RE
Investigative ophthalmology & visual science 2006 Oct;47(10):4507-12